Skip to main content
. 2016 Dec 28;2(4):370–380. doi: 10.1001/jamacardio.2016.4828

Figure 1. Action to Control Cardiovascular Risk in Diabetes (ACCORD)/ACCORD Follow-On Study (ACCORDION) CONSORT Diagram.

Figure 1.

In the ACCORD study, eligible participants underwent 2 sequential randomizations, the first to intensive vs standard glycemia therapy followed by a second randomization to intensive vs standard blood pressure or lipid treatment in a double 2 × 2 factorial design. In the ACCORD lipid trial, participants were randomized to either fenofibrate or placebo on a background of statin therapy. Following completion of ACCORD, a total of 4644 surviving Lipid trial participants agreed to extended passive (nontreatment) follow-up in ACCORDION. Rates of occurrence of cardiovascular end points during the original study and during extended follow-up were assessed in all study participants with censoring for the last date of follow-up.